Search

This paper updates to 2006 material first gathered in the late 1990s. Though Germany has about the same number of firms as the UK its biotechnology economy is far weaker, with many small firms employing few people, relatively low venture capital investment and little interest being shown by pharmaceuticals companies in licensing intellectual property. The reverse is the case in the UK even though the investor euphoria at the time of the first comparative study has not returned. A new policy of 'entrepreneurship outsourcing' has become visible in the UK as venture capital perceives a better business climate for biotechnology entrepreneurship in the USA. Recent developments of this kind may add to debilitating European problems, loosening more proximate links within national and regional innovation systems widely perceived as highly important elements in biotechnology cluster performance. [ABSTRACT FROM AUTHOR]